Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab and Ibrutinib for Relapsed/Refractory CLL (DIRECT)
NCT04230304Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Nov 2020
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Mayo Clinic. Started Nov 2020; status: terminated.
02
Drugs
daratumumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04230304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04230304.